OncLive® On Air Podcast Por OncLive® On Air arte de portada

OncLive® On Air

OncLive® On Air

De: OncLive® On Air
Escúchala gratis

In OncLive® On Air, you can expect to hear interviews with academic oncologists on the thought-provoking oncology presentations they give at the OncLive® State of the Science Summits. The topics in oncology vary, from systemic therapies, surgery, radiation therapy, to emerging therapeutic approaches in a particular type of cancer. This includes lung cancer, breast cancer, gastrointestinal cancers, hematologic malignancies, gynecologic cancers, genitourinary cancers, and more.

 Ciencia Higiene y Vida Saludable
Episodios
  • S16 Ep53: Live Tumor Board: Squamous Cell Carcinoma of the Head & Neck - Post-CRT Decisions in the Locally Advanced Setting

    S16 Ep53: Live Tumor Board: Squamous Cell Carcinoma of the Head & Neck - Post-CRT Decisions in the Locally Advanced Setting
    Apr 17 2026
    In this podcast, experts Barbara Burtness, MD; and Quynh-Thu Le, MD, FACR, FASTRO; discuss recent and ongoing trials and key updates in the management of locally advanced head and neck cancer.
    Más Menos
    33 m
  • S16 Ep52: Medical Crossfire®: PD-L1 Inhibition in Advanced Cutaneous Squamous Cell Carcinoma — Mechanistic Rationale and Clinical Application

    S16 Ep52: Medical Crossfire®: PD-L1 Inhibition in Advanced Cutaneous Squamous Cell Carcinoma — Mechanistic Rationale and Clinical Application
    Apr 15 2026
    In this podcast, experts April K.S. Salama, MD; Omid Hamid, MD; James M.G. Larkin, MD, PhD; and Sapna Patel, MD; discuss the data for immune checkpoint inhibitors used to treat advanced cutaneous squamous cell carcinoma, including a review of PD-1 versus PD-L1 inhibition.
    Más Menos
    31 m
  • S16 Ep51: Medical Crossfire®: Translating Risk Into Action—Redefining Adjuvant Strategies for Early HR+/HER2– Breast Cancer

    S16 Ep51: Medical Crossfire®: Translating Risk Into Action—Redefining Adjuvant Strategies for Early HR+/HER2– Breast Cancer
    Apr 14 2026
    In this podcast, experts Ann H. Partridge, MD, MPH; Saranya Chumsri, MD; and William J. Gradishar, MD, FASCO, FACP, discuss the roles of adjuvant chemotherapy and CDK4/6 inhibitors and neoadjuvant checkpoint inhibitors for patients with early-stage, hormone receptor–positive breast cancer.
    Más Menos
    29 m
Todavía no hay opiniones